Karin Jirström

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8261944/publications.pdf

Version: 2024-02-01

222 papers 12,878 citations

56 h-index 100 g-index

226 all docs

226 docs citations

times ranked

226

22048 citing authors

#	Article	IF	CITATIONS
1	<scp>PRR11</scp> unveiled as a top candidate biomarker within the <scp>RBM3</scp> â€regulated transcriptome in pancreatic cancer. Journal of Pathology: Clinical Research, 2022, 8, 65-77.	3.0	5
2	Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity. BMC Cancer, 2022, 22, 131.	2.6	3
3	OUP accepted manuscript. Clinical Chemistry, 2022, , .	3.2	5
4	Delineating the intra-patient heterogeneity of molecular alterations in treatment-na \tilde{A} -ve colorectal cancer with peritoneal carcinomatosis. Modern Pathology, 2022, , .	5.5	4
5	High Infiltration of CD68 ⁺ /CD163 ^{â^'} Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma. Journal of Innate Immunity, 2022, 14, 615-628.	3.8	8
6	Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer. Translational Oncology, 2022, 22, 101464.	3.7	3
7	T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival. Oncolmmunology, 2021, 10, 1921443.	4.6	14
8	Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study. Carcinogenesis, 2021, 42, 1314-1325.	2.8	8
9	Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumors. Journal of Surgical Oncology, 2021, 123, 1144-1156.	1.7	3
10	Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1. Cancers, 2021, 13, 871.	3.7	7
11	Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers. Cancers, 2021, 13, 1286.	3.7	1
12	Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. Frontiers in Oncology, 2021, 11, 626058.	2.8	6
13	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. EBioMedicine, 2021, 65, 103269.	6.1	25
14	Metabolic factors and the risk of small intestine cancers: Pooled study of 800 000 individuals in the metabolic syndrome and cancer project. International Journal of Cancer, 2021, 149, 66-74.	5.1	5
15	The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study. Frontiers in Oncology, 2021, 11, 642768.	2.8	4
16	The \hat{I}^3 -tubulin meshwork assists in the recruitment of PCNA to chromatin in mammalian cells. Communications Biology, 2021, 4, 767.	4.4	8
17	Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers. Archives of Pathology and Laboratory Medicine, 2020, 144, 1075-1085.	2.5	38
18	Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1. Molecular Cancer Research, 2020, 18, 644-656.	3.4	17

#	Article	lF	CITATIONS
19	A Functional Genomic Screen Identifies the Deubiquitinase USP11 as a Novel Transcriptional Regulator of $ER\hat{l}\pm$ in Breast Cancer. Cancer Research, 2020, 80, 5076-5088.	0.9	18
20	CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients. Breast Cancer Research, 2020, 22, 123.	5.0	14
21	Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer—Impact on Prognosis. Frontiers in Oncology, 2020, 10, 1278.	2.8	2
22	Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer. Biomarker Research, 2020, 8, 51.	6.8	4
23	Topographical Distribution and Spatial Interactions of Innate and Semi-Innate Immune Cells in Pancreatic and Other Periampullary Adenocarcinoma. Frontiers in Immunology, 2020, 11, 558169.	4.8	18
24	Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-NaÃ-ve Gastroesophageal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 534761.	2.8	20
25	Comprehensive analysis of RNA binding motif protein 3 (RBM3) in nonâ€small cell lung cancer. Cancer Medicine, 2020, 9, 5609-5619.	2.8	10
26	LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target. BMC Cancer, 2020, 20, 542.	2.6	58
27	Ovarian cancer subtypes and survival in relation to three comprehensive imaging parameters. Journal of Ovarian Research, 2020, 13, 26.	3.0	6
28	Inflammatory macrophage derived TNFÎ \pm downregulates estrogen receptor Î \pm via FOXO3a inactivation in human breast cancer cells. Experimental Cell Research, 2020, 390, 111932.	2.6	7
29	Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. International Journal of Cancer, 2020, 146, 3461-3473.	5.1	39
30	Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas. Scientific Reports, 2020, 10, 10373.	3.3	4
31	Re-evaluation of HER2 status in 606 breast cancersâ€"gene protein assay on tissue microarrays versus routine pathological assessment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 317-320.	2.8	12
32	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 2020, 577, 561-565.	27.8	1,209
33	Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study. BMC Cancer, 2020, 20, 308.	2.6	9
34	Complement inhibitor factor H expressed by breast cancer cells differentiates CD14 ⁺ human monocytes into immunosuppressive macrophages. Oncolmmunology, 2020, 9, 1731135.	4.6	20
35	Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. Life Science Alliance, 2020, 3, e202000893.	2.8	14
36	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. Clinical Cancer Research, 2019, 25, 7139-7150.	7.0	18

#	Article	IF	CITATIONS
37	Immune effector monocyte–neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21704-21714.	7.1	66
38	Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens. Oncolmmunology, 2019, 8, e1644108.	4.6	34
39	Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. Journal of Thoracic Oncology, 2019, 14, 628-640.	1.1	54
40	Expression of PD-L1 and PD-1 in Chemoradiotherapy-Na \tilde{A} -ve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. Frontiers in Oncology, 2019, 9, 136.	2.8	36
41	Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Scientific Reports, 2019, 9, 1319.	3.3	11
42	Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor immune cell composition. Oncolmmunology, 2019, 8, e1664275.	4.6	5
43	Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma. Biomarker Research, 2019, 7, 26.	6.8	1
44	Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma. Biomarker Research, 2019, 7, 1.	6.8	26
45	Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition. American Journal of Epidemiology, 2019, 188, 274-281.	3.4	6
46	Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases. Human Pathology, 2019, 84, 221-230.	2.0	39
47	Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: AÂMultinational Cohort Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1323-1331.e6.	4.4	99
48	Tumorâ€essociated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. International Journal of Cancer, 2018, 143, 515-526.	5.1	18
49	Hormonal factors and pancreatic cancer risk in women: The <scp>M</scp> almö <scp>D</scp> iet and <scp>C</scp> ancer <scp>S</scp> tudy. International Journal of Cancer, 2018, 143, 52-62.	5.1	30
50	Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. Journal of Translational Medicine, 2018, 16, 66.	4.4	18
51	Infiltration of γâ¢Î´T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. Cancer Biomarkers, 2018, 20, 395-409.	1.7	22
52	Tumor characteristics and prognosis in women with pregnancyâ€associated breast cancer. International Journal of Cancer, 2018, 142, 1343-1354.	5.1	75
53	Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. Journal of Clinical Pathology, 2018, 71, 451-462.	2.0	9
54	Ovarian cancer early detection by circulating <scp>CA</scp> 125 in the context of antiâ€ <scp>CA</scp> 125 autoantibody levels: Results from the <scp>EPIC</scp> cohort. International Journal of Cancer, 2018, 142, 1355-1360.	5.1	24

#	Article	IF	Citations
55	Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. Journal of Translational Medicine, 2018, 16, 290.	4.4	7
56	Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases. American Journal of Clinical Pathology, 2018, 150, 533-544.	0.7	27
57	Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients. Frontiers in Oncology, 2018, 8, 428.	2.8	8
58	A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk. Clinical Cancer Research, 2018, 24, 5895-5901.	7.0	88
59	Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment. Frontiers in Endocrinology, 2018, 9, 306.	3.5	7
60	Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. Oncolmmunology, 2018, 7, e1465165.	4.6	59
61	Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. Oncotarget, 2018, 9, 6188-6200.	1.8	13
62	MMP7 Modulation by Short- and Long-term Radiotherapy in Patients with Rectal Cancer. In Vivo, 2018, 32, 133-138.	1.3	5
63	Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2017, 140, 2246-2255.	5.1	39
64	Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. Modern Pathology, 2017, 30, 964-977.	5 . 5	17
65	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 3834-3845.	0.9	79
66	High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Research and Treatment, 2017, 164, 667-678.	2.5	79
67	Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study. Biomarker Research, 2017, 5, 10.	6.8	16
68	Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies. European Journal of Epidemiology, 2017, 32, 419-430.	5 . 7	17
69	The clinical impact of tumourâ€infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study. International Journal of Cancer, 2017, 141, 1654-1666.	5.1	65
70	Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer. European Journal of Cancer, 2017, 83, 279-289.	2.8	24
71	Multiâ€parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumourâ€typeâ€specific stroma phenotypes and a novel vascular biomarker. Journal of Pathology: Clinical Research, 2017, 3, 214-224.	3.0	8
72	Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma. BMC Medicine, 2017, 15, 101.	5 . 5	62

#	Article	IF	Citations
73	High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy–Treated Patients—Results from a Population-Based Breast Cancer Cohort. Clinical Cancer Research, 2017, 23, 766-777.	7.0	23
74	The prognostic impact of COXâ€2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. International Journal of Cancer, 2017, 140, 163-175.	5.1	19
75	Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer. Frontiers in Endocrinology, 2017, 8, 332.	3.5	5
76	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget, 2017, 8, 34796-34810.	1.8	45
77	The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype. Journal of Translational Medicine, 2017, 15, 152.	4.4	33
78	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS ONE, 2017, 12, e0182512.	2.5	27
79	Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups. Oncotarget, 2017, 8, 9093-9107.	1.8	13
80	The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget, 2017, 8, 72108-72126.	1.8	53
81	Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 848-859.	1.4	64
82	ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer. BMC Cancer, 2016, 16, 904.	2.6	82
83	Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology, 2016, 68, 230-240.	2.9	17
84	Prognostic impact of tumourâ€infiltrating B cells and plasma cells in colorectal cancer. International Journal of Cancer, 2016, 139, 1129-1139.	5.1	192
85	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	3.3	143
86	A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clinical Cancer Research, 2016, 22, 4664-4675.	7.0	80
87	Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Acta Oncológica, 2016, 55, 286-296.	1.8	14
88	Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. British Journal of Cancer, 2016, 114, 1117-1124.	6.4	57
89	Intra-tumour IgA1 is common in cancer and is correlated with poor prognosis in bladder cancer Heliyon, 2016, 2, e00143.	3.2	19
90	Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nature Communications, 2016, 7, 13050.	12.8	135

#	Article	IF	CITATIONS
91	Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. BMC Cancer, 2016, 16, 603.	2.6	33
92	Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clinical Pathology, 2016, 16, 13.	1.8	25
93	Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malm $ ilde{A}^{\P}$ Diet and Cancer Study. Biology of Sex Differences, 2016, 7, 66.	4.1	21
94	Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomarker Research, 2016, 4, 10.	6.8	25
95	Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. Journal of Ovarian Research, 2016, 9, 21.	3.0	76
96	Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer. Journal of Translational Medicine, 2016, 14, 128.	4.4	12
97	Pre-diagnostic meat and fibre intakes in relation to colorectal cancer survival in the European Prospective Investigation into Cancer and Nutrition. British Journal of Nutrition, 2016, 116, 316-325.	2.3	30
98	The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. Journal of Thoracic Oncology, 2016, 11, 862-872.	1.1	70
99	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS ONE, 2016, 11, e0148101.	2.5	25
100	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS ONE, 2016, 11, e0153533.	2.5	32
101	The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. PLoS ONE, 2016, 11, e0156497.	2.5	32
102	Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer. Oncotarget, 2016, 7, 76920-76933.	1.8	34
103	Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph nodeâ€negative breast cancer patients. FEBS Journal, 2015, 282, 3455-3473.	4.7	12
104	Fibre intake and incident colorectal cancer depending on fibre source, sex, tumour location and Tumour, Node, Metastasis stage. British Journal of Nutrition, 2015, 114, 959-969.	2.3	23
105	The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients. BMC Cancer, 2015, 15, 737.	2.6	10
106	Subtypes of fruit and vegetables, variety in consumption and risk of colon and rectal cancer in the <scp>E</scp> uropean <scp>P</scp> rospective <scp>I</scp> nvestigation into <scp>C</scp> ancer and <scp>N</scp> utrition. International Journal of Cancer, 2015, 137, 2705-2714.	5.1	45
107	Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer. PLoS ONE, 2015, 10, e0133449.	2.5	23
108	Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget, 2015, 6, 22028-22037.	1.8	61

#	Article	IF	CITATIONS
109	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology, 2015, 135, 1820-1828.	0.7	46
110	BRCA1â€like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Molecular Oncology, 2015, 9, 1528-1538.	4.6	54
111	Early diagnostic value of Bcl-3 localization in colorectal cancer. BMC Cancer, 2015, 15, 341.	2.6	12
112	Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. Journal of Translational Medicine, 2015, 13, 133.	4.4	53
113	Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence. Cancer Immunology, Immunotherapy, 2015, 64, 467-478.	4.2	25
114	Pre-diagnostic concordance with the WCRF/AICR guidelines and survival in European colorectal cancer patients: a cohort study. BMC Medicine, 2015, 13, 107.	5.5	66
115	Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort. Clinical Cancer Research, 2015, 21, 3640-3650.	7.0	64
116	LRIG1 is a prognostic biomarker in non-small cell lung cancer. Acta Oncol \tilde{A}^3 gica, 2015, 54, 1113-1119.	1.8	27
117	The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer, 2015, 15, 468.	2.6	44
118	Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. BMC Clinical Pathology, 2015, 15, 10.	1.8	43
119	Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clinical Pathology, 2015, 15, 8.	1.8	26
120	S100A9 expressed in ERâ^'PgRâ^' breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. British Journal of Cancer, 2015, 113, 1234-1243.	6.4	35
121	Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Research, 2015, 17, 130.	5.0	41
122	Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression. Cancer Letters, 2015, 356, 837-845.	7.2	28
123	Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer. PLoS ONE, 2015, 10, e0121300.	2.5	21
124	FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.	1.8	13
125	Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	1.8	148
126	Reduced Expression of the Polymeric Immunoglobulin Receptor in Pancreatic and Periampullary Adenocarcinoma Signifies Tumour Progression and Poor Prognosis. PLoS ONE, 2014, 9, e112728.	2.5	23

#	Article	IF	Citations
127	SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 649-659.	2.8	26
128	Prediagnostic Intake of Dairy Products and Dietary Calcium and Colorectal Cancer Survival—Results from the EPIC Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1813-1823.	2.5	34
129	Aberrantly activated claudin 6 and 18.2 as potential therapy targets in nonâ€small ell lung cancer. International Journal of Cancer, 2014, 135, 2206-2214.	5.1	82
130	Coffee and tea consumption, genotype-based <i>CYP1A2 </i> and <i>NAT2 </i> activity and colorectal cancer risk-Results from the EPIC cohort study. International Journal of Cancer, 2014, 135, 401-412.	5.1	35
131	Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. International Journal of Cancer, 2014, 135, 1949-1960.	5.1	42
132	Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. Journal of Translational Medicine, 2014, 12, 289.	4.4	49
133	Incident urothelial cancer in the Malm \tilde{A}^{\P} Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagnostic Pathology, 2014, 9, 189.	2.0	10
134	WNT5A-mediated Â-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis, 2014, 35, 784-794.	2.8	42
135	Investigation of molecular alterations of <i>><scp>AKT</scp>â€3</i> in tripleâ€negative breast cancer. Histopathology, 2014, 64, 660-670.	2.9	20
136	A systematic analysis of commonly used antibodies in cancer diagnostics. Histopathology, 2014, 64, 293-305.	2.9	13
137	Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial. Journal of Clinical Oncology, 2014, 32, 3613-3618.	1.6	184
138	Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. Journal of Investigative Dermatology, 2014, 134, 3000-3003.	0.7	8
139	High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomarker Research, 2014, 2, 11.	6.8	31
140	Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer. Journal of Ovarian Research, 2014, 7, 26.	3.0	21
141	The Target for Statins, HMG-CoA Reductase, Is Expressed in Ductal Carcinoma-In Situ and May Predict Patient Response to Radiotherapy. Annals of Surgical Oncology, 2014, 21, 2911-2919.	1.5	12
142	Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC Urology, 2014, 14, 36.	1.4	20
143	HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome. Diagnostic Pathology, 2014, 9, 78.	2.0	23
144	Use of a standardized diagnostic approach improves the prognostic information of histopathologic factors in pancreatic and periampullary adenocarcinoma. Diagnostic Pathology, 2014, 9, 80.	2.0	28

#	Article	IF	CITATIONS
145	Weight change later in life and colon and rectal cancer risk in participants in the EPIC-PANACEA study. American Journal of Clinical Nutrition, 2014, 99, 139-147.	4.7	33
146	Associations of Anthropometric Factors with KRAS and BRAF Mutation Status of Primary Colorectal Cancer in Men and Women: A Cohort Study. PLoS ONE, 2014, 9, e98964.	2.5	32
147	Low expression of SHP-2 is associated with less favorable prostate cancer outcomes. Tumor Biology, 2013, 34, 637-642.	1.8	13
148	Stage at diagnosis and mortality in women with pregnancy-associated breast cancer (PABC). Breast Cancer Research and Treatment, 2013, 139, 183-192.	2.5	47
149	Detecting EGFR alterations in clinical specimens—pitfalls and necessities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 755-764.	2.8	7
150	<scp>CDK</scp> â€mediated activation of the <scp>SCF^{FBXO}</scp> ²⁸ ubiquitin ligase promotes <scp>MYC</scp> â€driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Molecular Medicine, 2013, 5, 1067-1086.	6.9	61
151	STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer. Cancer Research, 2013, 73, 1287-1297.	0.9	144
152	Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Research and Treatment, 2013, 138, 499-508.	2.5	183
153	Sushi domainâ€containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase. FASEB Journal, 2013, 27, 2355-2366.	0.5	31
154	Contribution of Antibody-based Protein Profiling to the Human Chromosome-centric Proteome Project (C-HPP). Journal of Proteome Research, 2013, 12, 2439-2448.	3.7	48
155	Protein Expression Profiling of Formalin-Fixed Paraffin-Embedded Tissue Using Recombinant Antibody Microarrays. Journal of Proteome Research, 2013, 12, 5943-5953.	3.7	16
156	Low PIP4K2B Expression in Human Breast Tumors Correlates with Reduced Patient Survival: A Role for PIP4K2B in the Regulation of E-Cadherin Expression. Cancer Research, 2013, 73, 6913-6925.	0.9	41
157	Immunohistochemistry in the Differential Diagnostics of Primary Lung Cancer. American Journal of Clinical Pathology, 2013, 140, 37-46.	0.7	56
158	G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients. Clinical Cancer Research, 2013, 19, 1681-1692.	7.0	33
159	Histological specificity of alterations and expression of <i>KIT</i> and <i>KITLG</i> in nonâ€small cell lung carcinoma. Genes Chromosomes and Cancer, 2013, 52, 1088-1096.	2.8	17
160	Nuclear T-STAR Protein Expression Correlates with HER2 Status, Hormone Receptor Negativity and Prolonged Recurrence Free Survival in Primary Breast Cancer and Decreased Cancer Cell Growth In Vitro. PLoS ONE, 2013, 8, e70596.	2.5	2
161	Tumors with Nonfunctional Retinoblastoma Protein Are Killed by Reduced \hat{I}^3 -Tubulin Levels. Journal of Biological Chemistry, 2012, 287, 17241-17247.	3.4	25
162	Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research, 2012, 18, 4026-4036.	7.0	96

#	Article	IF	Citations
163	Coffee and tea consumption and the risk of ovarian cancer: a prospective cohort study and updated meta-analysis. American Journal of Clinical Nutrition, 2012, 95, 1172-1181.	4.7	56
164	miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential <i>In Vitro</i> . Clinical Cancer Research, 2012, 18, 6702-6713.	7.0	75
165	Downregulation of miR-92a Is Associated with Aggressive Breast Cancer Features and Increased Tumour Macrophage Infiltration. PLoS ONE, 2012, 7, e36051.	2.5	76
166	Wnt5a Induces a Tolerogenic Phenotype of Macrophages in Sepsis and Breast Cancer Patients. Journal of Immunology, 2012, 188, 5448-5458.	0.8	100
167	Multiple Miscarriages Are Associated with the Risk of Ovarian Cancer: Results from the European Prospective Investigation into Cancer and Nutrition. PLoS ONE, 2012, 7, e37141.	2.5	19
168	Serum concentrations of human chorionic gonadotropin beta and its association with survival in patients with colorectal cancer. Cancer Biomarkers, 2012, 11, 173-181.	1.7	7
169	CD99 is a novel prognostic stromal marker in nonâ€small cell lung cancer. International Journal of Cancer, 2012, 131, 2264-2273.	5.1	63
170	Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. International Journal of Cancer, 2012, 130, 2204-2210.	5.1	40
171	RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer. Translational Oncology, 2011, 4, 212-IN1.	3.7	54
172	Stromal Expression of \hat{l}^2 -Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer. Journal of Molecular Diagnostics, 2011, 13, 340-351.	2.8	23
173	Isolation and Characterization of Progenitor-Like Cells from Human Renal Proximal Tubules. American Journal of Pathology, 2011, 178, 828-837.	3.8	231
174	Anthropometric factors and ovarian cancer risk in the MalmÃ \P Diet and Cancer Study. Cancer Epidemiology, 2011, 35, 432-437.	1.9	11
175	Translational Database Selection and Multiplexed Sequence Capture for Up Front Filtering of Reliable Breast Cancer Biomarker Candidates. PLoS ONE, 2011, 6, e20794.	2.5	2
176	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948.	3.7	209
177	Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study. Journal of Translational Medicine, 2011, 9, 114.	4.4	51
178	Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. International Journal of Cancer, 2011, 129, 9-22.	5.1	46
179	The î"Np63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer. Cancer Research, 2011, 71, 1933-1944.	0.9	35
180	Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Modern Pathology, 2011, 24, 708-719.	5.5	31

#	Article	IF	CITATIONS
181	A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle, 2011, 10, 956-962.	2.6	41
182	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clinical Cancer Research, 2011, 17, 6083-6096.	7.0	330
183	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67.	9.4	1,486
184	The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochemical Society Transactions, 2011, 39, 663-668.	3.4	32
185	Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. Journal of Clinical Investigation, 2011, 121, 784-799.	8.2	177
186	Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2404-2415.	5.1	68
187	Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Research and Treatment, 2010, 120, 491-498.	2.5	69
188	Immunohistochemical detection of tyrosine phosphatase SHPâ€₁ predicts outcome after radical prostatectomy for localized prostate cancer. International Journal of Cancer, 2010, 126, 2296-2307.	5.1	28
189	p27 ^{Kip1} is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. International Journal of Cancer, 2010, 127, 2851-2858.	5.1	27
190	Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. Journal of Ovarian Research, 2010, 3, 14.	3.0	37
191	Polymorphisms in fatty acid metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis, 2010, 31, 466-472.	2.8	77
192	Plasma Folate Concentrations Are Positively Associated with Risk of Estrogen Receptor \hat{l}^2 Negative Breast Cancer in a Swedish Nested Case Control Study. Journal of Nutrition, 2010, 140, 1661-1668.	2.9	35
193	Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. Cancer Research, 2010, 70, 7776-7787.	0.9	25
194	Forkhead Box F1 Regulates Tumor-Promoting Properties of Cancer-Associated Fibroblasts in Lung Cancer. Cancer Research, 2010, 70, 2644-2654.	0.9	84
195	Down-Regulation of the Oncogene Cyclin D1 Increases Migratory Capacity in Breast Cancer and Is Linked to Unfavorable Prognostic Features. American Journal of Pathology, 2010, 177, 2886-2897.	3.8	58
196	Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2501-2506.	2.5	23
197	Molecular Evolution of Specific Human Antibody against MUC1 Mucin Results in Improved Recognition of the Antigen on Tumor Cells. Tumor Biology, 2009, 30, 221-231.	1.8	10
198	CRIM1 is localized to the podocyte filtration slit diaphragm of the adult human kidney. Nephrology Dialysis Transplantation, 2009, 24, 2038-2044.	0.7	12

#	Article	IF	Citations
199	The Prognostic Significance of Tryptophanyl-tRNA Synthetase in Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2949-2956.	2.5	71
200	Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer. Clinical Cancer Research, 2009, 15, 5552-5559.	7.0	22
201	Anthropometric factors in relation to different tumor biological subgroups of postmenopausal breast cancer. International Journal of Cancer, 2009, 124, 402-411.	5.1	36
202	Increased claudinâ€4 expression is associated with poor prognosis and high tumour grade in breast cancer. International Journal of Cancer, 2009, 124, 2088-2097.	5.1	128
203	JAMâ€A expression positively correlates with poor prognosis in breast cancer patients. International Journal of Cancer, 2009, 125, 1343-1351.	5.1	115
204	Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Modern Pathology, 2009, 22, 1564-1574.	5.5	69
205	Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer. American Journal of Pathology, 2009, 175, 334-341.	3.8	215
206	HMGâ€CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. International Journal of Cancer, 2008, 123, 1146-1153.	5.1	55
207	Hypoxia-Inducible Factor-2α Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer. Cancer Research, 2008, 68, 9212-9220.	0.9	130
208	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. Clinical Cancer Research, 2008, 14, 2681-2689.	7.0	83
209	15-Prostaglandin Dehydrogenase Expression Alone or in Combination with ACSM1 Defines a Subgroup of the Apocrine Molecular Subtype of Breast Carcinoma. Molecular and Cellular Proteomics, 2008, 7, 1795-1809.	3.8	31
210	Nuclear expression of the non–B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood, 2008, 111, 800-805.	1.4	185
211	CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. International Journal of Cancer, 2007, 120, 1434-1443.	5.1	98
212	Breast tumours following combined hormone replacement therapy express favourable prognostic factors. International Journal of Cancer, 2007, 120, 2202-2207.	5.1	51
213	Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical and Experimental Metastasis, 2007, 24, 69-78.	3.3	118
214	Hypoxia inducible factorâ€1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. International Journal of Cancer, 2006, 118, 2609-2616.	5.1	70
215	Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research, 2006, 12, 6459-6468.	7.0	100
216	CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clinical Cancer Research, 2006, 12, 6421-6431.	7.0	123

#	Article	IF	CITATIONS
217	Association Between Pak1 Expression and Subcellular Localization and Tamoxifen Resistance in Breast Cancer Patients. Journal of the National Cancer Institute, 2006, 98, 671-680.	6.3	177
218	High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 4614-4618.	7.0	121
219	Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification. Cancer Research, 2005, 65, 8009-8016.	0.9	117
220	ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene, 2005, 24, 4370-4379.	5.9	106
221	Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression. Breast Cancer Research and Treatment, 2005, 89, 313-316.	2.5	11
222	Cyclin E Overexpression Obstructs Infiltrative Behavior in Breast Cancer: A Novel Role Reflected in the Growth Pattern of Medullary Breast Cancers. Cancer Research, 2005, 65, 9727-9734.	0.9	25